Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy

David R. Holmes(Mayo Clinic), Saibal Kar(Cedars-Sinai Medical Center), Matthew J. Price(Scripps Health), Brian Whisenant(Intermountain Medical Center), Horst Sievert(Cardiovascular Center Frankfurt), Shephal K. Doshi(Pacific Heart Institute), Kenneth Huber(Saint Luke's Hospital), Vivek Y. Reddy(Icahn School of Medicine at Mount Sinai)

Journal of the American College of Cardiology

July 1, 2014

10.1016/j.jacc.2014.04.029

Cited by 1,795

Abstract

Related Papers

Bayesian Data Analysis

Andrew Gelman, John B. Carlin, Hal S. Stern et al.|Unknown|1995|13.8k

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

Manesh R. Patel, Kenneth W. Mahaffey, Jyotsna Garg et al.|New England Journal of Medicine|2011|9.4k

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Philip A. Wolf, Robert D. Abbott, W B Kannel|Stroke|1991|7.4k

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Robert G. Hart, Lesly A. Pearce, Maria I. Aguilar|Annals of Internal Medicine|2007|4.8k

Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial

David R. Holmes, Vivek Y. Reddy, Zoltan G. Turi et al.|The Lancet|2009|2.2k